2021 Fiscal Year Final Research Report
Development of a novel antibody therapy for Alzheimer's disease using anti-Abeta oligomeric minimal fragment antibodies
| Project/Area Number |
19K07998
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Oita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松原 悦朗 大分大学, 医学部, 教授 (70219468)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | Aβオリゴマー / アルツハイマー型認知症 / Aβオリゴマー抗体 / CDRペプチド / マイクロダイアリシス |
|---|
| Outline of Final Research Achievements |
Aiming to develop a curative therapy for Alzheimer's disease (AD), we have independently developed "minimal fragment antibodies" that recognize the molecules responsible for AD (Aβoligomers). In this study, we examined the pharmacokinetics of these antibodies in the brain and their effects on memory impairment using an animal model of AD. We found that the antibodies were easily transferred into the brain by peripheral administration and distributed in the hippocampus and cerebral cortex. The antibodies also improved memory impairment in model mice to the same level as in normal mice. Since these antibodies have been found to be inexpensive and highly effective, we will continue our research to elucidate the action mechanism in detail and to develop a formulation for clinical application in human.
|
| Free Research Field |
神経内科学，認知症，行動薬理学
|
| Academic Significance and Societal Importance of the Research Achievements |
我々が新規開発した最小フラグメント抗体は，優れた脳内移行性を持ち，抗Aβオリゴマーフルボディ抗体に匹敵する記憶障害予防効果を持つだけでなく，従来の抗Aβオリゴマー抗体と異なり神経細胞内にも作用点を持つ可能性を見出した．以上より，本抗体が細胞内Aβオリゴマーの挙動の理解や制御を通してADの病態解明に大きく貢献することが期待できる．社会的には，急速な高齢社会の大きな問題であるADに対して，安価で効果的な根治療法の開発に道を開き，以って医療介護における人的経済的負担の軽減に貢献できると考える．
|
